This trial is evaluating whether Varying Doses of Background and Boost RT will improve 1 primary outcome and 4 secondary outcomes in patients with Mesothelioma. Measurement will happen over the course of Up to five years.
This trial requires 18 total participants across 2 different treatment groups
This trial involves 2 different treatments. Varying Doses Of Background And Boost RT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
The cause of mesothelioma is known to be environmental. Chemical factors are also thought to be able to induce tumors that are genetically susceptible to develop. It is clear that there are a considerable number of mesotheliomas which were triggered by environmental factors. It is therefore logical that these cancers are difficult to treat as these factors might be able to cause recurrence and survival failure. Thus treatment of mesothelioma will need to incorporate biological modifiers that can prevent or slow down an existing cancer from spreading.
Common treatment for mesothelioma includes surgery, chemotherapy, and radiation therapy (chemotherapy and radiation therapy are often used as a palliative measure). Surgery and chemotherapy may involve the creation of a surgical or interventional pneumonectomy or a lung parenchyma transplant. There is no cure for mesothelioma, so treatment is focused on managing symptoms and maintaining quality of life. Mesothelioma occurs most frequently in people over 50 who are exposed to asbestos.
Because the median survival after diagnosis is only 2 months, and only one-quarter of metastatic mesothelioma patients are known to be curable with surgery, radiation therapy, chemotherapy, and/or surgery, there are important and potentially fruitful therapeutic possibilities for mesothelioma. The identification of therapeutic targets that are frequently aberrant in mesothelioma may enable a more effective and personalized approach to the management.
Signs of mesothelioma including paraneoplastic neurological disorders and pain due to a tumor can be detected. In the absence of clinical symptoms, a workup including magnetic resonance imaging may reveal the presence of a large malignant tumor, even in the asymptomatic patients.
Mesothelioma occurrence appears to be higher in areas with a high density of asbestos work sites. A number of geographic subtypes of mesothelioma can be identified. The distribution of age-adjusted rates is inversely related to age and to male sex. The highest occurrences are in Iowa, Mississippi, Maine, Massachusetts, Virginia, and Maryland. Mesothelioma occurs most frequently between the ages of 75 and 79 years and has a peak of occurrence from 80 to 89 years old. However, the age distribution of occurrences varies across the United States and around the world, with occurrences in Ireland being much lower than ones in the United States.
The prevalence of malignant pleural mesothelioma (or MPM) has increased with decreasing occupational exposures to asbestos in the United States. This increase is likely because of the increased use of asbestos in home repairs, construction, and other industries.
An estimated 20% of the people with mesothelioma will be diagnosed before age 65, and 4% will be over 90 in the age group 70+. This indicates that mesothelioma could prove to be the primary cancer for an unusually long period of time. Mesothelioma often occurs later in men (average age of diagnosis of men is 74, whereas it is 67 for women).
In a recent study, findings of this study do not support the notion that the use of different doses of background irradiation and boost irradiation may be safe for patients receiving two-field WLP or IM-WLP breast irradiation. An exception is a small decrease in the incidence of Grade 2 myelotoxicosis with the use of 2.8 Gy background dose and 10 Gy boost dose in the WLP-IM combination.
Findings from a recent study of the present study indicate that no specific family factors are responsible, at least in most families, for the presence of mesothelioid tumors. It is highly advisable to prevent and treat all the exposed families with malignant tumors.
Background radiation (BR) is typically used for radiotherapy of all tumors in the treatment of cancer in order to kill cancer cells and reduce the tumor size. The boost radiation protocol is the radiation therapy with an additional dose of radiation tailored to each individual patient in order to improve the treatment outcome and prolong overall survival.
Patients benefited from either the background or boost regimen. The most significant statistical differences between groups were found at 12 weeks, when both treatment regimens were more effective than placebo.
There are no real chances to develop it. That was proven when it was first mentioned and its symptoms became more well known. In fact, the first symptoms may be mistaken for other, less serious illnesses. It was said that it is diagnosed by the very small amount of cancer that seems to grow from the testicles or from the abdomen. It may be found when a person is already quite high-risk because of the age and other factors. These factors are genetic.